China Aiming To Slash Hospital Medical Cost Growth By Half
This article was originally published in PharmAsia News
Executive Summary
Transitionally strong urban hospital market will be cut even deeper, forcing drug makers to actively expand to lower-tiered county hospitals and grassroots clinics for growth.
You may also be interested in...
2016 Review: Rapid Change Defines China Regulatory Environment
If you missed some of the many significant events in China’s policy and regulatory landscape in 2016, here is your opportunity to catch up on month-by-month developments.
Bounce Or More Bumps? New China Market Data Offer Bit Of Both
Two new sets of data on growth in China’s turbulent pharma sector paint a mixed and complex picture, indicating both challenges and opportunities ahead for multinational and domestic firms in the country.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.